RxDoctor Payments Data

Michal Wall, MD

Internal Medicine · Jupiter, FLNPI 1871701706

Payments from drug & device makers

$2,954in general payments, 2019–2025

Across 100 payments — averaging $29.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$621
  • AstraZeneca$610
  • AbbVie$331
  • Lilly USA, LLC$292
  • GSK$286
  • Kvk-tech, Inc.$161
  • plus $653 from 14 others

What the payments were for

  • Food & beverage$2,954100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,954 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$402,150
Medicare patients
760
Services billed
4,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$74,869
MounjaroTirzepatide57$58,080
EliquisApixaban42$54,499
JardianceEmpagliflozin24$26,477
RybelsusSemaglutide13$24,021
XareltoRivaroxaban14$22,844
FarxigaDapagliflozin Propanediol14$19,872
LinzessLinaclotide16$18,541
MyrbetriqMirabegron11$14,101
SynthroidLevothyroxine Sodium86$8,293
Rosuvastatin Calcium346$4,706
Levothyroxine Sodium386$3,791
Duloxetine Hcl27$3,408
Mesalamine11$3,190
Atorvastatin Calcium341$3,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$621$98,88985 claims
Lilly USA, LLCMounjaro$292$58,08057 claims
PfizerEliquis, Paxlovid$103$55,92858 claims
AbbVieLinzess, Synthroid$331$26,834102 claims
Johnson & JohnsonXarelto$29$22,84414 claims
AstraZenecaFarxiga$610$19,87214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →